Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract manufacturing and formulation services. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone856-697-1441
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$67.25 million
Profitability
Miscellaneous
Employees183
Next Earnings Date3/21/2019 (Estimated)
OptionableOptionable
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent Inc (NASDAQ:TLGT) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01). The firm earned $18.29 million during the quarter, compared to analyst estimates of $19.80 million. Teligent had a negative return on equity of 44.64% and a negative net margin of 54.17%. View Teligent's Earnings History.
When is Teligent's next earnings date?
What price target have analysts set for TLGT?
1 analysts have issued 12-month price targets for Teligent's stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Teligent's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 94.8% from the stock's current price. View Analyst Price Targets for Teligent.
What is the consensus analysts' recommendation for Teligent?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teligent.
Has Teligent been receiving favorable news coverage?
Media stories about TLGT stock have trended positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teligent earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include Urovant Sciences (UROV), Tyme Technologies (TYME), Aduro BioTech (ADRO), Dermira (DERM), American Brivision (Holding) (ABVC), Albireo Pharma (ALBO), Evelo Biosciences (EVLO), Abeona Therapeutics (ABEO), Minerva Neurosciences (NERV), AC Immune (ACIU), Magenta Therapeutics (MGTA), XBiotech (XBIT), Adamas Pharmaceuticals (ADMS), OptiNose (OPTN) and Intec Pharma (NTEC).
What other stocks do shareholders of Teligent own?
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 44)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 53)
- Mr. Martin Wilson, Gen. Counsel (Age 42)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 49)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 50)
Who are Teligent's major shareholders?
Teligent's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Elk Creek Partners LLC (9.08%), Prosight Management LP (6.60%), BlackRock Inc. (5.43%), Broadfin Capital LLC (5.25%), AMI Asset Management Corp (5.05%) and Eversept Partners LP (4.18%). Company insiders that own Teligent stock include Carole Ben-Maimon, Damian Finio, Jason Grenfell-Gardner, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Institutional Ownership Trends for Teligent.
Which major investors are selling Teligent stock?
TLGT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Northpointe Capital LLC, Broadfin Capital LLC and Kopp Investment Advisors LLC. View Insider Buying and Selling for Teligent.
Which major investors are buying Teligent stock?
TLGT stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Elk Creek Partners LLC, SCW Capital Management LP, GSA Capital Partners LLP, Eversept Partners LP, Sanders Morris Harris LLC, AMI Asset Management Corp and SG Americas Securities LLC. Company insiders that have bought Teligent stock in the last two years include Carole Ben-Maimon, Damian Finio, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Insider Buying and Selling for Teligent.
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $1.54.
How big of a company is Teligent?
Teligent has a market capitalization of $82.81 million and generates $67.25 million in revenue each year. The company earns $-15,190,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Teligent employs 183 workers across the globe.
What is Teligent's official website?
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (NASDAQ TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
